SHR-1826
SHR-1826 is a pharmaceutical drug with 6 clinical trials. Currently 3 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
4
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
3
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Clinical Trials (6)
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6